Understanding bone loss in people living with HIV and its connection to the gut and microbiome.
Predictors of Antiretroviral Immunereconstitution Bone Loss - the Gut and the Microbiome
This study is looking at how HIV and the medications used to treat it can affect bone health, especially why some people lose more bone than others after starting treatment, and how aging plays a part in this.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10911978 on NIH RePORTER |
What this research studies
This research investigates how bone loss occurs in individuals living with HIV, particularly focusing on the effects of antiretroviral therapy (ART) and the role of the gut microbiome. It aims to understand why some patients experience significant bone loss after starting ART while others do not, and how aging compounds this issue. By examining immune responses and microbial interactions, the study seeks to identify predictors of bone loss and potential interventions. Patients may be monitored for changes in bone density and immune function over time.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are living with HIV and are starting or have recently started antiretroviral therapy.
Not a fit: Patients who are not living with HIV or those who are not undergoing antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing bone loss in people living with HIV, enhancing their overall health and quality of life.
How similar studies have performed: Previous research has indicated that immune activation and gut health play significant roles in bone health for individuals with HIV, suggesting that this approach could yield valuable insights.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Ofotokun, Ighovwerha — Emory University
- Study coordinator: Ofotokun, Ighovwerha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.